Floatz logo

Acalabrutinib

Iatrogenic

Polish Lymphoma Research GroupSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Iatrogenic cohort.

Asset / SponsorPhaseRating
Isosorbide Dinitrate
Ukrainian Medical Stomatological Academy
Phase 4BB
Bisoprolol Fumarate
Ukrainian Medical Stomatological Academy
Phase 4BB
Rosuvastatin
Ukrainian Medical Stomatological Academy
Phase 4BB
Aspirin
Ukrainian Medical Stomatological Academy
Phase 4BB
Pioglitazone
Ukrainian Medical Stomatological Academy
Phase 4BB
Corpril
Ukrainian Medical Stomatological Academy
Phase 4BB
Hydrocortisone
Mahidol University
Phase 2CCC
Valproic Acid
Sun Yat-sen University
UnknownC

Same molecule, other indications

Acalabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
follicular lymphomaActive
BB
Indicative · Phase 2
70 / 100
View asset →
diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →